NYSE ARCA | ETF
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index.
The underlying index was composed of common stocks ofU. S. biotechnology and genome companies.
These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc.
It is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| NBIX | Neurocrine Biosciences Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 5.63% |
| NTRA | Natera Inc | Healthcare | Diagnostics & Research | 5.40% |
| GILD | Gilead Sciences Inc | Healthcare | Drug Manufacturers - General | 5.11% |
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 4.85% |
| BIIB | Biogen Inc | Healthcare | Drug Manufacturers - General | 4.79% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 4.79% |
| IMGN | ImmunoGen Inc | Healthcare | Biotechnology | 4.78% |
| UTHR | United Therapeutics Corporation | Healthcare | Drug Manufacturers - Specialty & Generic | 4.77% |
| ALNY | Alnylam Pharmaceuticals Inc | Healthcare | Biotechnology | 4.56% |
| ILMN | Illumina Inc | Healthcare | Diagnostics & Research | 4.44% |
| PTGX | Protagonist Therapeutics Inc | Healthcare | Biotechnology | 4.08% |
| BPMC | Blueprint Medicines Corp | Healthcare | Biotechnology | 4.00% |
| AXSM | Axsome Therapeutics Inc | Healthcare | Biotechnology | 3.73% |
| BCRX | BioCryst Pharmaceuticals Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 3.70% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 3.55% |
| TGTX | TG Therapeutics Inc | Healthcare | Biotechnology | 3.50% |
| CPRX | Catalyst Pharmaceuticals Inc | Healthcare | Biotechnology | 3.42% |
| EXEL | Exelixis Inc | Healthcare | Biotechnology | 3.32% |
| QGEN | Qiagen NV | Healthcare | Diagnostics & Research | 3.23% |
| ACAD | ACADIA Pharmaceuticals Inc | Healthcare | Biotechnology | 3.22% |